Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors

Abstract Background Rett syndrome (RTT) is a progressive neurodevelopmental disease that is characterized by abnormalities in cognitive, social, and motor skills. RTT is often caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2). The mechanism by which impaired MeCP...

Full description

Bibliographic Details
Main Authors: Suzy Varderidou-Minasian, Lisa Hinz, Dominique Hagemans, Danielle Posthuma, Maarten Altelaar, Vivi M. Heine
Format: Article
Language:English
Published: BMC 2020-05-01
Series:Molecular Autism
Subjects:
Online Access:http://link.springer.com/article/10.1186/s13229-020-00344-3
id doaj-40cea582b1ad4dd7b69a21ef5be27180
record_format Article
collection DOAJ
language English
format Article
sources DOAJ
author Suzy Varderidou-Minasian
Lisa Hinz
Dominique Hagemans
Danielle Posthuma
Maarten Altelaar
Vivi M. Heine
spellingShingle Suzy Varderidou-Minasian
Lisa Hinz
Dominique Hagemans
Danielle Posthuma
Maarten Altelaar
Vivi M. Heine
Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
Molecular Autism
Rett syndrome
iPSC
Neuron differentiation
Quantitative mass spectrometry
TMT-10plex
author_facet Suzy Varderidou-Minasian
Lisa Hinz
Dominique Hagemans
Danielle Posthuma
Maarten Altelaar
Vivi M. Heine
author_sort Suzy Varderidou-Minasian
title Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
title_short Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
title_full Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
title_fullStr Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
title_full_unstemmed Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitors
title_sort quantitative proteomic analysis of rett ipsc-derived neuronal progenitors
publisher BMC
series Molecular Autism
issn 2040-2392
publishDate 2020-05-01
description Abstract Background Rett syndrome (RTT) is a progressive neurodevelopmental disease that is characterized by abnormalities in cognitive, social, and motor skills. RTT is often caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2). The mechanism by which impaired MeCP2 induces the pathological abnormalities in the brain is not understood. Both patients and mouse models have shown abnormalities at molecular and cellular level before typical RTT-associated symptoms appear. This implies that underlying mechanisms are already affected during neurodevelopmental stages. Methods To understand the molecular mechanisms involved in disease onset, we used an RTT patient induced pluripotent stem cell (iPSC)-based model with isogenic controls and performed time-series of proteomic analysis using in-depth high-resolution quantitative mass spectrometry during early stages of neuronal development. Results We provide mass spectrometry-based quantitative proteomic data, depth of about 7000 proteins, at neuronal progenitor developmental stages of RTT patient cells and isogenic controls. Our data gives evidence of proteomic alteration at early neurodevelopmental stages, suggesting alterations long before the phase that symptoms of RTT syndrome become apparent. Significant changes are associated with the GO enrichment analysis in biological processes cell-cell adhesion, actin cytoskeleton organization, neuronal stem cell population maintenance, and pituitary gland development, next to protein changes previously associated with RTT, i.e., dendrite morphology and synaptic deficits. Differential expression increased from early to late neural stem cell phases, although proteins involved in immunity, metabolic processes, and calcium signaling were affected throughout all stages analyzed. Limitations The limitation of our study is the number of RTT patients analyzed. As the aim of our study was to investigate a large number of proteins, only one patient was considered, of which 3 different RTT iPSC clones and 3 isogenic control iPSC clones were included. Even though this approach allowed the study of mutation-induced alterations due to the usage of isogenic controls, results should be validated on different RTT patients to suggest common disease mechanisms. Conclusions During early neuronal differentiation, there are consistent and time-point specific proteomic alterations in RTT patient cells carrying exons 3–4 deletion in MECP2. We found changes in proteins involved in pathway associated with RTT phenotypes, including dendrite morphology and synaptogenesis. Our results provide a valuable resource of proteins and pathways for follow-up studies, investigating common mechanisms involved during early disease stages of RTT syndrome.
topic Rett syndrome
iPSC
Neuron differentiation
Quantitative mass spectrometry
TMT-10plex
url http://link.springer.com/article/10.1186/s13229-020-00344-3
work_keys_str_mv AT suzyvarderidouminasian quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
AT lisahinz quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
AT dominiquehagemans quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
AT danielleposthuma quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
AT maartenaltelaar quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
AT vivimheine quantitativeproteomicanalysisofrettipscderivedneuronalprogenitors
_version_ 1724656288229490688
spelling doaj-40cea582b1ad4dd7b69a21ef5be271802020-11-25T03:10:56ZengBMCMolecular Autism2040-23922020-05-0111111510.1186/s13229-020-00344-3Quantitative proteomic analysis of Rett iPSC-derived neuronal progenitorsSuzy Varderidou-Minasian0Lisa Hinz1Dominique Hagemans2Danielle Posthuma3Maarten Altelaar4Vivi M. Heine5Biomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of UtrechtDepartment of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit AmsterdamBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of UtrechtDepartment of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit AmsterdamBiomolecular Mass Spectrometry and Proteomics, Bijvoet Center for Biomolecular Research and Utrecht Institute for Pharmaceutical Sciences, University of UtrechtDepartment of Complex Trait Genetics, Center for Neurogenomics and Cognitive Research, Amsterdam Neuroscience, Vrije Universiteit AmsterdamAbstract Background Rett syndrome (RTT) is a progressive neurodevelopmental disease that is characterized by abnormalities in cognitive, social, and motor skills. RTT is often caused by mutations in the X-linked gene encoding methyl-CpG binding protein 2 (MeCP2). The mechanism by which impaired MeCP2 induces the pathological abnormalities in the brain is not understood. Both patients and mouse models have shown abnormalities at molecular and cellular level before typical RTT-associated symptoms appear. This implies that underlying mechanisms are already affected during neurodevelopmental stages. Methods To understand the molecular mechanisms involved in disease onset, we used an RTT patient induced pluripotent stem cell (iPSC)-based model with isogenic controls and performed time-series of proteomic analysis using in-depth high-resolution quantitative mass spectrometry during early stages of neuronal development. Results We provide mass spectrometry-based quantitative proteomic data, depth of about 7000 proteins, at neuronal progenitor developmental stages of RTT patient cells and isogenic controls. Our data gives evidence of proteomic alteration at early neurodevelopmental stages, suggesting alterations long before the phase that symptoms of RTT syndrome become apparent. Significant changes are associated with the GO enrichment analysis in biological processes cell-cell adhesion, actin cytoskeleton organization, neuronal stem cell population maintenance, and pituitary gland development, next to protein changes previously associated with RTT, i.e., dendrite morphology and synaptic deficits. Differential expression increased from early to late neural stem cell phases, although proteins involved in immunity, metabolic processes, and calcium signaling were affected throughout all stages analyzed. Limitations The limitation of our study is the number of RTT patients analyzed. As the aim of our study was to investigate a large number of proteins, only one patient was considered, of which 3 different RTT iPSC clones and 3 isogenic control iPSC clones were included. Even though this approach allowed the study of mutation-induced alterations due to the usage of isogenic controls, results should be validated on different RTT patients to suggest common disease mechanisms. Conclusions During early neuronal differentiation, there are consistent and time-point specific proteomic alterations in RTT patient cells carrying exons 3–4 deletion in MECP2. We found changes in proteins involved in pathway associated with RTT phenotypes, including dendrite morphology and synaptogenesis. Our results provide a valuable resource of proteins and pathways for follow-up studies, investigating common mechanisms involved during early disease stages of RTT syndrome.http://link.springer.com/article/10.1186/s13229-020-00344-3Rett syndromeiPSCNeuron differentiationQuantitative mass spectrometryTMT-10plex